Evidence map›Paper›PMID 39774263›Full record

ArticleThe Journal of antibiotics2025

Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.

Alicja Sękowska

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. HighMicrobiology spectrum · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alicja SękowskaDepartment of Microbiology, Nicolaus Copernicus University, The Ludwik Rydygiers Collegium Medicum, Bydgoszcz, Poland. asekowska@cm.umk.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamDrug Resistance, Multiple, BacterialKlebsiella pneumoniaeMicrobial Sensitivity TestsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesDrug CombinationsHumansKlebsiella InfectionsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasescarbapenemaseDrug Combinations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.